Merck shares have risen 45% year-to-date, driven by strong sales of its KEYTRUDA drug and upcoming regulatory milestones. Between September and October, Merck faces several FDA decision deadlines for new drug applications, including WINREVAIR and WELIREG combinations, plus a major data release for its personalized cancer vaccine developed with Moderna at the ESMO conference in late October. Success in these events could boost analyst price targets and push the stock toward $200, despite risks from KEYTRUDA patent expiration and recent acquisition charges. Investors should watch these catalysts closely as they could cause stock volatility in either direction.
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial ...
